Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00626340 · ClinicalTrials.gov registry record · Phase 4
Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder
A Phase 4 study of Depression and Menopause, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT00626340 is a Phase 4 study of Depression and Menopause that has completed, run by University of Pennsylvania. The registered enrollment target is 18 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00626340, a Phase 4 study of Depression and Menopause, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose this study is to measure cortical gama-aminobutyric acid levels (GABA) levels in menopausal women with major depressive disorder and healthy subjects using nuclear magnetic resonance spectroscopy (MRS). Measurements will be compared in 1) menopausal healthy subjects before and after estrogen replacement, and after fourteen days of medroxyprogesterone administration; and 2) in depressed menopausal subjects before and after treatment of their depression with antidepressant alone, estrogen alone or antidepressant plus estrogen. Cortical GABA levels will be correlated with plasma GABA and neurosteroid levels. Neurosteroids to be measured include progesterone, allopregnanolone, pregnenolone, and pregnenolone sulfate.
Conditions Studied
Interventions
- DRUG MDD diagnosis and Estrogen treatment
- DRUG MDD diagnosis and Fluoxetine treatment
- DRUG MDD diagnosis with both Estrogen and Fluoxetine treatment
- DRUG No depression and estrogen treatment
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 1999-07 |
| Est. Completion | 2008-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00626340
The ClinicalTrials.gov registry entry for NCT00626340 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (98% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 4 interventions - of which MDD diagnosis and Estrogen treatment is the first listed.
NCT00626340 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00626340 about?
NCT00626340 is a clinical study titled "Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder". The purpose this study is to measure cortical gama-aminobutyric acid levels (GABA) levels in menopausal women with major depressive disorder and healthy subjects using nuclear magnetic resonance spectroscopy (MRS). Measurements will be compared in 1) menopausal healthy subjects before and after estr...
What is the current status of trial NCT00626340?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 1999-07. Estimated completion is 2008-07.
What conditions does trial NCT00626340 study?
This clinical trial studies the following conditions: Depression, Menopause.
What interventions are being tested in trial NCT00626340?
The interventions under investigation include: MDD diagnosis and Estrogen treatment (DRUG), MDD diagnosis and Fluoxetine treatment (DRUG), MDD diagnosis with both Estrogen and Fluoxetine treatment (DRUG), No depression and estrogen treatment (DRUG).
Who is sponsoring clinical trial NCT00626340?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00626340 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.